



Atty. Docket: 58769.000011

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of :

EMORINE, L., *et al.*

Serial No.: 09/895,211

Filed: July 02, 2001

For: INTRON/EXON STRUCTURE OF THE HUMAN AND MOUSE
BETA3-ADRENERGIC RECEPTOR GENES

Examiner: Ulm, J.

Group Art Unit: 1646

RECEIVED
AUG 14 2003
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Mail Stop Issue Fee

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants respectfully request consideration of the references listed on the attached Form PTO/SB/08A. Copies of the references listed are also enclosed.

These references are recited in the specification but do not appear to have been formally disclosed in a Form PTO/SB/08A. In order that these references may be listed on the front page of the issued patent, Applicants respectfully request that the Examiner consider the references cited on the Form PTO/SB/08A and that the Examiner indicate that the references have been considered in this application by returning a copy of the Form PTO/SB/08A with the Examiner's initials in the left column per MPEP 609.

Applicants' submission of this Information Disclosure Statement (IDS) shall not be construed as an admission that the cited references are prior art to the present invention, or that the cited references qualify as printed publications. The submission of this IDS also shall not be construed as a representation that a prior art search has been performed.



Atty. Docket: 58769.000011

In accordance with 37 CFR § 1.97, this IDS is being filed after a first Office Action on the merits but before payment of the issue fee for the above-identified patent application. As such, this IDS is accompanied by a check in the amount of \$180.00. If any fees are necessitated by the filing of this Information Disclosure Statement, please charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

Dated: August 11, 2003

By:

Robert M. Schulman
Registration No. 31,196

David H. Milligan
Registration No. 42,893

HUNTON & WILLIAMS LLP
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, DC 20006-1109
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)

RMS/DHM/cbt

RECEIVED
AUG 14 2003
TECH CENTER 1600/2900

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/895,211
Filing Date	July 2, 2001
First Named Inventor	Laurent Emorine
Group Art Unit	1646
Examiner Name	John D. Ulm
Attorney Docket Number	58769.000011

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	U1					
	U2					
	U3					

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T _s
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P1	ARCH, J.R.S. et al., "β-adrenergic-mediated control of thermogenesis, body composition and glucose homeostasis," in: <i>Obesity and Cachexia: Physiological Mechanisms and New Approaches to Pharmacological Control</i> (England, John Wiley & Sons Ltd, 1991), pp. 241-268.	
	P2	ARCH, J.R.S., "The brown adipocyte β-adrenoceptor," <i>Proceedings of the Nutrition Society</i> , Vol. 48 (1989), pp. 215-223.	
	P3	BIANCHETTI, A & L. MANARA, "In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical β-adrenoceptors in rat colon," <i>Br. J. Pharmacol.</i> , Vol. 100 (1990), pp. 831-839.	
	P4	BOND, R.A. & D.E. CLARKE, "Agonist and antagonist characterization of a putative adrenoceptor with distinct pharmacological properties from the α- and β-subtypes," <i>Br. J. Pharmacol.</i> , Vol. 95 (1988), pp. 723-734.	


Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	09/895,211
Filing Date	July 2, 2001
First Named Inventor	Laurent Emorine
Group Art Unit	1646
Examiner Name	John D. Ulm
Attorney Docket Number	58769.000011

RECEIVED
AUG 14 2003
TECH CENTER 1600, 2900

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P5	COLEMAN, R.A. et al., "β-adrenoceptors in guinea-pig gastric fundus - are they the same as the 'atypical' β-adrenoceptors in rat adipocytes?", <i>Br. J. Pharmacol.</i> , Vol. 90: Proceedings Supplement (Mar. 1987), p. 40P.	
	P6	COTECCHIA, S. et al., "Molecular cloning and expression of the cDNA for the hamster α ₁ -adrenergic receptor," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 85 (Oct. 1988), pp. 7159-7163.	
	P7	DIXON, R.A.F. et al., "Structure and function of G-protein coupled receptors," <i>Annual Reports in Medicinal Chemistry</i> (1988), pp. 221-233.	
	P8	GRANNEMAN, J.G. & C.J. WHITTY, "CGP 12177A modulates brown fat adenylate cyclase activity by interacting with two distinct receptor sites," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 256, no. 2 (1991), pp. 421-425.	
	P9	KOBILKA, B.K. et al., "Cloning, sequencing, and expression of the gene coding for the human platelet α ₂ -adrenergic receptor," <i>Science</i> , Vol. 238 (Oct. 30, 1987), pp. 650-656.	
	P10	KRIEF, S. et al., "Tissue distribution of β ₃ -adrenergic receptor mRNA in man," <i>J. Clin. Invest.</i> , Vol. 91 (Jan. 1993), pp. 344-349.	
	P11	STRADER, C.D. et al., "Structural basis of β-adrenergic receptor function," <i>The FASEB Journal</i> , Vol. 3 (May 1989), pp. 1825-1832.	
	P12	ZAAGSMA, J. & S.R. NAHORSKI, "Is the adipocyte β-adrenoceptor a prototype for the recently cloned atypical 'β ₃ -adrenoceptor'?" <i>TIPS</i> , Vol. 11 (Jan. 1990), pp. 3-7.	
	P13		
	P14		

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450 Alexandria, VA 22313-1450